Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

100-Year Human Aging Study

2 september 2026 uppdaterad av: William Brandenburg, MD, Longevity Metrics, Inc.

100-Year Human Aging Study: Prospective Longitudinal Validation of Multi-System Health Measurements Against Mortality and Aging Outcomes

The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed clinical sites, mobile clinical sites, and an online participation pathway (current and future) to undergo comprehensive multi-system health screening and longitudinal follow-up until death. Participants are followed to determine whether measurements taken at enrollment and repeated across the lifespan - individually and in combination - predict all-cause mortality, cause-specific mortality, incident serious disease, and functional disability. The study is designed to generate the surrogate endpoint validation data that longevity medicine currently lacks.

Studieöversikt

Detaljerad beskrivning

All currently existing longevity measures are surrogate endpoints that have not been prospectively validated against actual mortality and aging outcomes. The 100-Year Human Aging Study is a prospective, pragmatic, observational trial that addresses this gap by enrolling participants in comprehensive clinical screening and following them longitudinally until death to determine which measurements - alone and in combination - are predictive of mortality, serious disease, and functional disability.

The study prioritizes dynamic measurements: the physiological, cognitive, social, and environmental capacities that change with aging and are most likely to carry predictive signal for mortality and functional outcomes. These include cardiorespiratory fitness (cardiopulmonary exercise testing with ventilatory threshold analysis), strength (grip, explosive power, functional movement), mobility and balance, neurocognitive performance, sensory function (vision, hearing, smell, light touch), and metabolic function (oral glucose tolerance, continuous glucose monitoring), in addition to other testing. Structural and imaging assessments include body composition and bone mineral density by DEXA, echocardiography, resting and stress electrocardiography, spirometry, retinal fundus photography, and vascular ultrasound. Laboratory measures are drawn on-site and processed through a CLIA-certified reference laboratory. Complete medical, surgical, family, social, occupational, and environmental histories are obtained at each visit.

Participation ranges from single-service visits - including standalone DEXA, cardiopulmonary exercise testing, laboratory panel testing, and sleep studies - to the full two-visit comprehensive screening battery. All participation pathways contribute clinical data to the longitudinal mortality and aging outcomes linkage framework regardless of service level. Participants are encouraged to return for repeat testing to build longitudinal health trajectories across the lifespan.

At enrollment and across longitudinal follow-up, the study platform generates individualized investigational constructs including biological age estimate, predicted death age, and predicted cause of death profile. These are explicitly investigational hypotheses, not validated clinical standards. Their predictive validity relative to actual mortality, aging outcomes, and functional disability is a central scientific question this study is designed to answer, both for individual measures and for composite multi-system models.

All data are archived in their highest-dimensional raw form to preserve the ability to apply future analytical methods retroactively. Participants are followed with periodic contact and offered repeat screening throughout the lifespan. Longitudinal outcomes ascertainment includes all-cause mortality, cause-specific mortality, incident serious health events, chronic disease diagnosis, functional independence, disability status, and health behavior change.

Study sites and participation pathways. The 100-Year Human Aging Study is conducted across all Longevity Metrics participation pathways, current and future: the Boulder Human Performance Lab (fixed flagship laboratory); mobile screening units including the Health Ahead Bus; any additional fixed or mobile Longevity Metrics laboratory established during the study period; and an online participation pathway through which participants enroll and contribute structured data without in-person screening. All pathways operate under a single protocol with identical procedures, data management, informed consent, and safety standards.

This study is one of four that compound into one system. The Human Observatory Study (NCT07646782) validates sociodemographic and environmental data against the same outcomes, and receives each model's geographic residuals. The Health Ahead Comparative Effectiveness Study (NCT07669168) moves the screening toward increasing automation and mobility while maintaining quality. The Longevity Metrics AI/ML Development Study (NCT pending approval) builds the models that make automation, prediction, and broad utilization possible. This study supplies the clinical data and validates what it means for health, disease, disability, and death.

Studietyp

Observationell

Inskrivning (Beräknad)

1000000

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Ja

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Participants of all ages, health statuses, and demographic backgrounds presenting for comprehensive preventive health screening at fixed or mobile clinical sites. No exclusions based on health status, geographic location, language, or population group. Participants with limited decision-making capacity may be enrolled with consent from a legally authorized representative. The study actively seeks to enroll participants across the full human lifespan including older adults and centenarians.

Beskrivning

Inclusion Criteria:

  • Age 18 years or older
  • Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative
  • Willing to participate in longitudinal follow-up

Exclusion Criteria:

  • Age under 18 years

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
All-Cause Mortality
Tidsram: From enrollment until death, assessed periodically, up to 100 years
Vital status ascertained through longitudinal follow-up contact, mortality record linkage, and health data network linkage using probabilistic matching on name, date of birth, and address history.
From enrollment until death, assessed periodically, up to 100 years
Cause-Specific Mortality
Tidsram: From enrollment until death, assessed periodically, up to 100 years
Cause of death ascertained via death certificate and mortality record linkage.
From enrollment until death, assessed periodically, up to 100 years

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Cause-Specific Mortality Prediction Accuracy
Tidsram: From enrollment until death, assessed periodically, up to 100 years
Concordance between predicted cause of death profile generated at enrollment and actual cause of death ascertained at follow-up.
From enrollment until death, assessed periodically, up to 100 years
Incident Serious Adverse Health Events
Tidsram: Periodically from enrollment until death, up to 100 years
New diagnosis of myocardial infarction, stroke, cancer, dementia, heart failure, atrial fibrillation, sepsis, venous thromboembolism, COPD, chronic hypoxia, or major fracture ascertained via periodic follow-up contact and health data network linkage.
Periodically from enrollment until death, up to 100 years
Incident Chronic Disease
Tidsram: Periodically from enrollment until death, up to 100 years
New diagnosis of type 2 diabetes, hypertension, COPD, chronic kidney disease, metabolic syndrome, or osteoporosis ascertained via self-report and health data network linkage.
Periodically from enrollment until death, up to 100 years
Functional Independence and Disability Status
Tidsram: Periodically from enrollment until death, up to 100 years
Activities of daily living, instrumental activities of daily living, and self-reported disability status ascertained via periodic health survey using validated open-source instruments. Higher composite scores indicate greater functional independence. Specific instruments will be selected prior to first follow-up contact and documented in the statistical analysis plan.
Periodically from enrollment until death, up to 100 years
Biological Age Estimate Prediction Accuracy
Tidsram: Periodically from enrollment until death, up to 100 years
Concordance between investigational biological age estimate and actual mortality outcomes at longitudinal follow-up.
Periodically from enrollment until death, up to 100 years
Health Behavior Change: Composite Self-Report and Repeat Screening Index
Tidsram: Periodically from enrollment until death, up to 100 years
Health behavior change assessed through two complementary measures aggregated into a single index: validated composite self-report survey administered at periodic follow-up, and change in pre-specified clinical measurements at repeat screening. Improvement in objective clinical measurements (cardiorespiratory fitness, body composition, metabolic biomarkers, and related parameters) serves as the primary behavioral activation signal. Self-report domains including health behaviors and preventive care utilization provide supporting context. Both are combined into a single participant-level health activation index. Higher scores indicate greater engagement with health-promoting behaviors and measurable clinical improvement.
Periodically from enrollment until death, up to 100 years
Multi-System Predictor Modeling: Predictive Performance
Tidsram: Periodically from enrollment until death, up to 100 years
Performance of a unified multi-domain measurement framework in predicting all-cause mortality and incident serious disease. The framework integrates clinical, biological, behavioral, social, occupational, and environmental data into a single composite model. Performance is reported for the full composite model, with pre-specified secondary reporting for individual predictor domains and domain combinations to identify which inputs are independently predictive, which are redundant, and which combinations provide additive or synergistic predictive value. Metrics are specified in the statistical analysis plan.
Periodically from enrollment until death, up to 100 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: William E Brandenburg, MD, Longevity Metrics, Inc.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

9 februari 2025

Primärt slutförande (Beräknad)

31 december 2099

Avslutad studie (Beräknad)

31 december 2099

Studieregistreringsdatum

Först inskickad

11 april 2026

Först inskickad som uppfyllde QC-kriterierna

30 april 2026

Första postat (Faktisk)

4 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

8 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual participant data are not shared. The complete participant record includes facial and voice recordings, genomic data, and neighborhood-resolution geography, and cannot be de-identified; it is never released. Identifiable data are accessed only by approved researchers working within Longevity Metrics secure facilities under data use agreements, with no data removed. Specific derived, aggregate, and statistical outputs are de-identified to HIPAA Safe Harbor standards and may be published, shared with collaborators, or contributed to open-access research databases. Models, risk estimates, and analytic findings derived from the research data may be provided to external organizations or used commercially; no participant record and no dataset containing participant data is transferred.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera